egaten

Generic: triclabendazole

Labeler: novartis pharmaceuticals corporation
NDC Directory HUMAN PRESCRIPTION DRUG NDA Inactive Finished

Drug Facts

Product Profile

Brand Name egaten
Generic Name triclabendazole
Labeler novartis pharmaceuticals corporation
Dosage Form TABLET
Routes
ORAL
Active Ingredients

triclabendazole 250 mg/1

Manufacturer
Novartis Pharmaceuticals Corporation

Identifiers & Regulatory

Product NDC 0078-0937
Product ID 0078-0937_59dff6dc-c0b0-4f26-9738-32f8a6540033
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category NDA
Application Number NDA208711
Listing Expiration 2026-12-31
Marketing Start 2019-02-13

Pharmacologic Class

Established (EPC)
anthelmintic [epc]
Mechanism of Action
cytochrome p450 2c19 inhibitors [moa] cytochrome p450 1a2 inhibitors [moa] cytochrome p450 2a6 inhibitors [moa] cytochrome p450 2b6 inhibitors [moa] cytochrome p450 2c8 inhibitors [moa] cytochrome p450 2c9 inhibitors [moa] cytochrome p450 2d6 inhibitors [moa] cytochrome p450 3a inhibitors [moa]
Chemical Structure
anthelmintics [cs]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 00780937
Hyphenated Format 0078-0937

Supplemental Identifiers

RxCUI
2118606 2118612
UNII
4784C8E03O
NUI
N0000175481 M0001301 N0000182140 N0000182138 N0000193937 N0000182139 N0000187062 N0000185504 N0000182137 N0000190114

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name egaten (source: ndc)
Generic Name triclabendazole (source: ndc)
Application Number NDA208711 (source: ndc)
Routes
ORAL
source: ndc

Resolved Composition

Strengths
  • 250 mg/1
source: ndc
Packaging
  • 4 TABLET in 1 BLISTER PACK (0078-0937-91)
source: ndc

Packages (1)

0078-0937-91 4 TABLET in 1 BLISTER PACK (0078-0937-91)

Ingredients (1)

triclabendazole (250 mg/1)

Linked Drug Pages (1)

EGATEN ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["ORAL"], "spl_id": "59dff6dc-c0b0-4f26-9738-32f8a6540033", "openfda": {"nui": ["N0000175481", "M0001301", "N0000182140", "N0000182138", "N0000193937", "N0000182139", "N0000187062", "N0000185504", "N0000182137", "N0000190114"], "unii": ["4784C8E03O"], "rxcui": ["2118606", "2118612"], "spl_set_id": ["5552884e-10ea-450c-9658-d3d4f33c946e"], "pharm_class_cs": ["Anthelmintics [CS]"], "pharm_class_epc": ["Anthelmintic [EPC]"], "pharm_class_moa": ["Cytochrome P450 2C19 Inhibitors [MoA]", "Cytochrome P450 1A2 Inhibitors [MoA]", "Cytochrome P450 2A6 Inhibitors [MoA]", "Cytochrome P450 2B6 Inhibitors [MoA]", "Cytochrome P450 2C8 Inhibitors [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]"], "manufacturer_name": ["Novartis Pharmaceuticals Corporation"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "4 TABLET in 1 BLISTER PACK (0078-0937-91)", "package_ndc": "0078-0937-91", "marketing_start_date": "20190213"}], "brand_name": "EGATEN", "product_id": "0078-0937_59dff6dc-c0b0-4f26-9738-32f8a6540033", "dosage_form": "TABLET", "pharm_class": ["Anthelmintic [EPC]", "Anthelmintics [CS]", "Cytochrome P450 1A2 Inhibitors [MoA]", "Cytochrome P450 2A6 Inhibitors [MoA]", "Cytochrome P450 2B6 Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "Cytochrome P450 2C8 Inhibitors [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]"], "product_ndc": "0078-0937", "generic_name": "triclabendazole", "labeler_name": "Novartis Pharmaceuticals Corporation", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "EGATEN", "active_ingredients": [{"name": "TRICLABENDAZOLE", "strength": "250 mg/1"}], "application_number": "NDA208711", "marketing_category": "NDA", "marketing_start_date": "20190213", "listing_expiration_date": "20261231"}